Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 2/2011

Open Access 01-02-2011 | Article

Medical-grade honey enriched with antimicrobial peptides has enhanced activity against antibiotic-resistant pathogens

Authors: P. H. S. Kwakman, L. de Boer, C. P. Ruyter-Spira, T. Creemers-Molenaar, J. P. F. G. Helsper, C. M. J. E. Vandenbroucke-Grauls, S. A. J. Zaat, A. A. te Velde

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2011

Login to get access

Abstract

Honey has potent activity against both antibiotic-sensitive and -resistant bacteria, and is an interesting agent for topical antimicrobial application to wounds. As honey is diluted by wound exudate, rapid bactericidal activity up to high dilution is a prerequisite for its successful application. We investigated the kinetics of the killing of antibiotic-resistant bacteria by RS honey, the source for the production of Revamil® medical-grade honey, and we aimed to enhance the rapid bactericidal activity of RS honey by enrichment with its endogenous compounds or the addition of antimicrobial peptides (AMPs). RS honey killed antibiotic-resistant isolates of Pseudomonas aeruginosa, Staphylococcus epidermidis, Enterococcus faecium, and Burkholderia cepacia within 2 h, but lacked such rapid activity against methicillin-resistant S. aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. It was not feasible to enhance the rapid activity of RS honey by enrichment with endogenous compounds, but RS honey enriched with 75 μM of the synthetic peptide Bactericidal Peptide 2 (BP2) showed rapid bactericidal activity against all species tested, including MRSA and ESBL E. coli, at up to 10–20-fold dilution. RS honey enriched with BP2 rapidly killed all bacteria tested and had a broader spectrum of bactericidal activity than either BP2 or honey alone.
Literature
1.
go back to reference Walsh C (2003) Antibiotics: actions, origins, resistance. American Society for Microbiology (ASM) Press, Washington Walsh C (2003) Antibiotics: actions, origins, resistance. American Society for Microbiology (ASM) Press, Washington
2.
go back to reference Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10:S122–S129CrossRefPubMed Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10:S122–S129CrossRefPubMed
4.
go back to reference Cooper RA, Molan PC, Harding KG (2002) The sensitivity to honey of Gram-positive cocci of clinical significance isolated from wounds. J Appl Microbiol 93:857–863CrossRefPubMed Cooper RA, Molan PC, Harding KG (2002) The sensitivity to honey of Gram-positive cocci of clinical significance isolated from wounds. J Appl Microbiol 93:857–863CrossRefPubMed
5.
go back to reference Efem SEE (1988) Clinical observations on the wound healing properties of honey. Br J Surg 75:679–681CrossRefPubMed Efem SEE (1988) Clinical observations on the wound healing properties of honey. Br J Surg 75:679–681CrossRefPubMed
8.
go back to reference Lusby PE, Coombes A, Wilkinson JM (2002) Honey: a potent agent for wound healing? J Wound Ostomy Continence Nurs 29:295–300PubMed Lusby PE, Coombes A, Wilkinson JM (2002) Honey: a potent agent for wound healing? J Wound Ostomy Continence Nurs 29:295–300PubMed
9.
go back to reference Simon A, Traynor K, Santos K, Blaser G, Bode U, Molan P (2009) Medical honey for wound care—still the ‘latest resort’? Evid Based Complement Alternat Med 6:165–173CrossRefPubMed Simon A, Traynor K, Santos K, Blaser G, Bode U, Molan P (2009) Medical honey for wound care—still the ‘latest resort’? Evid Based Complement Alternat Med 6:165–173CrossRefPubMed
10.
go back to reference Molan PC (1992) The antibacterial activity of honey. 2. Variation in the potency of the antibacterial activity. Bee World 73:59–76 Molan PC (1992) The antibacterial activity of honey. 2. Variation in the potency of the antibacterial activity. Bee World 73:59–76
11.
go back to reference Allen KL, Molan PC, Reid GM (1991) A survey of the antibacterial activity of some New Zealand honeys. J Pharm Pharmacol 43:817–822PubMed Allen KL, Molan PC, Reid GM (1991) A survey of the antibacterial activity of some New Zealand honeys. J Pharm Pharmacol 43:817–822PubMed
12.
go back to reference Adams CJ, Boult CH, Deadman BJ, Farr JM, Grainger MN, Manley-Harris M, Snow MJ (2008) Isolation by HPLC and characterisation of the bioactive fraction of New Zealand manuka (Leptospermum scoparium) honey. Carbohydr Res 343:651–659CrossRefPubMed Adams CJ, Boult CH, Deadman BJ, Farr JM, Grainger MN, Manley-Harris M, Snow MJ (2008) Isolation by HPLC and characterisation of the bioactive fraction of New Zealand manuka (Leptospermum scoparium) honey. Carbohydr Res 343:651–659CrossRefPubMed
13.
go back to reference Mavric E, Wittmann S, Barth G, Henle T (2008) Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Manuka (Leptospermum scoparium) honeys from New Zealand. Mol Nutr Food Res 52:483–489CrossRefPubMed Mavric E, Wittmann S, Barth G, Henle T (2008) Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Manuka (Leptospermum scoparium) honeys from New Zealand. Mol Nutr Food Res 52:483–489CrossRefPubMed
14.
go back to reference Postmes T, van den Bogaard AE, Hazen M (1995) The sterilization of honey with cobalt 60 gamma radiation: a study of honey spiked with spores of Clostridium botulinum and Bacillus subtilis. Experientia 51:986–989CrossRefPubMed Postmes T, van den Bogaard AE, Hazen M (1995) The sterilization of honey with cobalt 60 gamma radiation: a study of honey spiked with spores of Clostridium botulinum and Bacillus subtilis. Experientia 51:986–989CrossRefPubMed
15.
go back to reference Kwakman PHS, Van den Akker JPC, Güçlü A, Aslami H, Binnekade JM, de Boer L, Boszhard L, Paulus F, Middelhoek P, te Velde AA, Vandenbroucke-Grauls CMJE, Schultz MJ, Zaat SAJ (2008) Medical-grade honey kills antibiotic-resistant bacteria in vitro and eradicates skin colonization. Clin Infect Dis 46:1677–1682CrossRefPubMed Kwakman PHS, Van den Akker JPC, Güçlü A, Aslami H, Binnekade JM, de Boer L, Boszhard L, Paulus F, Middelhoek P, te Velde AA, Vandenbroucke-Grauls CMJE, Schultz MJ, Zaat SAJ (2008) Medical-grade honey kills antibiotic-resistant bacteria in vitro and eradicates skin colonization. Clin Infect Dis 46:1677–1682CrossRefPubMed
16.
go back to reference Kwakman PHS, te Velde AA, de Boer L, Speijer D, Vandenbroucke-Grauls CMJE, Zaat SAJ (2010) How honey kills bacteria. FASEB J 24:2576–2582CrossRefPubMed Kwakman PHS, te Velde AA, de Boer L, Speijer D, Vandenbroucke-Grauls CMJE, Zaat SAJ (2010) How honey kills bacteria. FASEB J 24:2576–2582CrossRefPubMed
17.
18.
19.
go back to reference Kobayashi S, Takeshima K, Park CB, Kim SC, Matsuzaki K (2000) Interactions of the novel antimicrobial peptide buforin 2 with lipid bilayers: proline as a translocation promoting factor. Biochemistry 39:8648–8654CrossRefPubMed Kobayashi S, Takeshima K, Park CB, Kim SC, Matsuzaki K (2000) Interactions of the novel antimicrobial peptide buforin 2 with lipid bilayers: proline as a translocation promoting factor. Biochemistry 39:8648–8654CrossRefPubMed
20.
go back to reference Epand RM, Vogel HJ (1999) Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1462:11–28CrossRefPubMed Epand RM, Vogel HJ (1999) Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1462:11–28CrossRefPubMed
21.
go back to reference Matsuzaki K (1999) Why and how are peptide–lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim Biophys Acta 1462:1–10CrossRefPubMed Matsuzaki K (1999) Why and how are peptide–lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim Biophys Acta 1462:1–10CrossRefPubMed
22.
go back to reference Devine DA, Hancock RE (2002) Cationic peptides: distribution and mechanisms of resistance. Curr Pharm Des 8:703–714CrossRefPubMed Devine DA, Hancock RE (2002) Cationic peptides: distribution and mechanisms of resistance. Curr Pharm Des 8:703–714CrossRefPubMed
23.
go back to reference Al Naiemi N, Duim B, Savelkoul PH, Spanjaard L, de Jonge E, Bart A, Vandenbroucke-Grauls CM, de Jong MD (2005) Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology. J Clin Microbiol 43:4862–4864CrossRef Al Naiemi N, Duim B, Savelkoul PH, Spanjaard L, de Jonge E, Bart A, Vandenbroucke-Grauls CM, de Jong MD (2005) Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology. J Clin Microbiol 43:4862–4864CrossRef
24.
go back to reference White JW Jr, Subers MH (1963) Studies on honey inhibine. 2. A chemical assay. J Apic Res 2:93–100 White JW Jr, Subers MH (1963) Studies on honey inhibine. 2. A chemical assay. J Apic Res 2:93–100
25.
go back to reference Dankert J, van der Werff J, Zaat SAJ, Joldersma W, Klein D, Hess J (1995) Involvement of bactericidal factors from thrombin-stimulated platelets in clearance of adherent viridans streptococci in experimental infective endocarditis. Infect Immun 63:663–671PubMed Dankert J, van der Werff J, Zaat SAJ, Joldersma W, Klein D, Hess J (1995) Involvement of bactericidal factors from thrombin-stimulated platelets in clearance of adherent viridans streptococci in experimental infective endocarditis. Infect Immun 63:663–671PubMed
26.
go back to reference Sørensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N (1997) The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 90:2796–2803PubMed Sørensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N (1997) The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 90:2796–2803PubMed
27.
go back to reference Frohm Nilsson M, Sandstedt B, Sørensen O, Weber G, Borregaard N, Ståhle-Bäckdahl M (1999) The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 67:2561–2566PubMed Frohm Nilsson M, Sandstedt B, Sørensen O, Weber G, Borregaard N, Ståhle-Bäckdahl M (1999) The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 67:2561–2566PubMed
28.
go back to reference Kwakman PHS, te Velde AA, Vandenbroucke-Grauls CMJE, van Deventer SJH, Zaat SAJ (2006) Treatment and prevention of Staphylococcus epidermidis experimental biomaterial-associated infection by bactericidal peptide 2. Antimicrob Agents Chemother 50:3977–3983CrossRefPubMed Kwakman PHS, te Velde AA, Vandenbroucke-Grauls CMJE, van Deventer SJH, Zaat SAJ (2006) Treatment and prevention of Staphylococcus epidermidis experimental biomaterial-associated infection by bactericidal peptide 2. Antimicrob Agents Chemother 50:3977–3983CrossRefPubMed
29.
go back to reference Bang LM, Buntting C, Molan P (2003) The effect of dilution on the rate of hydrogen peroxide production in honey and its implications for wound healing. J Altern Complement Med 9:267–273CrossRefPubMed Bang LM, Buntting C, Molan P (2003) The effect of dilution on the rate of hydrogen peroxide production in honey and its implications for wound healing. J Altern Complement Med 9:267–273CrossRefPubMed
30.
go back to reference Lineaweaver W, Mcmorris S, Soucy D, Howard R (1985) Cellular and bacterial toxicities of topical antimicrobials. Plast Reconstr Surg 75:394–396CrossRefPubMed Lineaweaver W, Mcmorris S, Soucy D, Howard R (1985) Cellular and bacterial toxicities of topical antimicrobials. Plast Reconstr Surg 75:394–396CrossRefPubMed
31.
go back to reference Wilson JR, Mills JG, Prather ID, Dimitrijevich SD (2005) A toxicity index of skin and wound cleansers used on in vitro fibroblasts and keratinocytes. Adv Skin Wound Care 18:373–378CrossRefPubMed Wilson JR, Mills JG, Prather ID, Dimitrijevich SD (2005) A toxicity index of skin and wound cleansers used on in vitro fibroblasts and keratinocytes. Adv Skin Wound Care 18:373–378CrossRefPubMed
32.
33.
go back to reference Fujiwara S, Imai J, Fujiwara M, Yaeshima T, Kawashima T, Kobayashi K (1990) A potent antibacterial protein in royal jelly. Purification and determination of the primary structure of royalisin. J Biol Chem 265:11333–11337PubMed Fujiwara S, Imai J, Fujiwara M, Yaeshima T, Kawashima T, Kobayashi K (1990) A potent antibacterial protein in royal jelly. Purification and determination of the primary structure of royalisin. J Biol Chem 265:11333–11337PubMed
34.
go back to reference Casteels-Josson K, Zhang W, Capaci T, Casteels P, Tempst P (1994) Acute transcriptional response of the honeybee peptide-antibiotics gene repertoire and required post-translational conversion of the precursor structures. J Biol Chem 269:28569–28575PubMed Casteels-Josson K, Zhang W, Capaci T, Casteels P, Tempst P (1994) Acute transcriptional response of the honeybee peptide-antibiotics gene repertoire and required post-translational conversion of the precursor structures. J Biol Chem 269:28569–28575PubMed
35.
36.
go back to reference Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820CrossRefPubMed Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820CrossRefPubMed
37.
go back to reference Stitt AW (2003) The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 75:95–108CrossRefPubMed Stitt AW (2003) The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 75:95–108CrossRefPubMed
38.
go back to reference Zanetti M, Gennaro R, Romeo D (1995) Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374:1–5CrossRefPubMed Zanetti M, Gennaro R, Romeo D (1995) Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374:1–5CrossRefPubMed
39.
go back to reference Lehrer RI, Ganz T (2002) Cathelicidins: a family of endogenous antimicrobial peptides. Curr Opin Hematol 9:18–22CrossRefPubMed Lehrer RI, Ganz T (2002) Cathelicidins: a family of endogenous antimicrobial peptides. Curr Opin Hematol 9:18–22CrossRefPubMed
40.
go back to reference Niyonsaba F, Ogawa H (2005) Protective roles of the skin against infection: Implication of naturally occurring human antimicrobial agents beta-defensins, cathelicidin LL-37 and lysozyme. J Dermatol Sci 40:157–168CrossRefPubMed Niyonsaba F, Ogawa H (2005) Protective roles of the skin against infection: Implication of naturally occurring human antimicrobial agents beta-defensins, cathelicidin LL-37 and lysozyme. J Dermatol Sci 40:157–168CrossRefPubMed
41.
go back to reference Pütsep K, Carlsson G, Boman HG, Andersson M (2002) Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 360:1144–1149CrossRefPubMed Pütsep K, Carlsson G, Boman HG, Andersson M (2002) Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 360:1144–1149CrossRefPubMed
42.
go back to reference Govan JR, Deretic V (1996) Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60:539–574PubMed Govan JR, Deretic V (1996) Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60:539–574PubMed
43.
go back to reference Clore GM, Appella E, Yamada M, Matsushima K, Gronenborn AM (1990) Three-dimensional structure of interleukin 8 in solution. Biochemistry 29:1689–1696CrossRefPubMed Clore GM, Appella E, Yamada M, Matsushima K, Gronenborn AM (1990) Three-dimensional structure of interleukin 8 in solution. Biochemistry 29:1689–1696CrossRefPubMed
44.
go back to reference Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI (1998) Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42:2206–2214PubMed Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI (1998) Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42:2206–2214PubMed
45.
go back to reference Cooper RA, Wigley P, Burton NF (2000) Susceptibility of multiresistant strains of Burkholderia cepacia to honey. Lett Appl Microbiol 31:20–24CrossRefPubMed Cooper RA, Wigley P, Burton NF (2000) Susceptibility of multiresistant strains of Burkholderia cepacia to honey. Lett Appl Microbiol 31:20–24CrossRefPubMed
Metadata
Title
Medical-grade honey enriched with antimicrobial peptides has enhanced activity against antibiotic-resistant pathogens
Authors
P. H. S. Kwakman
L. de Boer
C. P. Ruyter-Spira
T. Creemers-Molenaar
J. P. F. G. Helsper
C. M. J. E. Vandenbroucke-Grauls
S. A. J. Zaat
A. A. te Velde
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2011
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-010-1077-x

Other articles of this Issue 2/2011

European Journal of Clinical Microbiology & Infectious Diseases 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.